Findings in the Area of Antineoplastics Reported from Yonsei University (Comparison of the Safety and Efficacy of Biodegradable Polymer Biolimus-Eluting Stents and Durable Polymer Everolimus-Eluting Stents: Propensity Score-Matched Analysis)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting from Gangwon Do, South Korea, by NewsRx journalists, research stated, "We investigated and compared the clinical outcomes between biodegradable polymer biolimus-eluting stents (BES) and durable polymer everolimus-eluting stents (EES) in a single-center prospective registry. There is limited data regarding the safety and efficacy of the biodegradable BES compared to second-generation drug-eluting stents."
The news correspondents obtained a quote from the research from Yonsei University, "From January 2010 to April 2012, a total of 1,279 patients were treated with BES (n = 647) or EES (n = 632) in a single center. We included 1,231 patients (BES = 625, EES = 606) after excluding 48 patients (BES = 22, EES = 26) with acute myocardial infarction accompanied by cardiogenic shock. The 1-year incidences of target lesion failure (TLF), patient-oriented composite outcomes (POCO), and stent thrombosis (ST) after the index procedure were compared in propensity score-matched analyses. Propensity score matching yielded 406 well-balanced pairs (EES 406, BES-B 406). In the propensity-matched population, the 1-year incidence of TLF (BES 3.0% vs. EES = 2.5%, P = 0.666) and POCO (BES = 5.4% vs. EES 6.4%, P = 0.552) were similar between the 2 groups. In addition, the incidence of definite or probable ST was also similar (BES = 0.74% vs. EES = 0.74%, P = 1.000). In subgroup analysis, the number of patients who reached the primary end-point did not differ significantly between the 2 groups."
According to the news reporters, the research concluded: "In a single-center registry with unrestricted use of EES and BES-B, these stents showed comparable efficacy and safety in terms of TLF, POCO, and ST at 1-year follow-up."
For more information on this research see: Comparison of the Safety and Efficacy of Biodegradable Polymer Biolimus-Eluting Stents and Durable Polymer Everolimus-Eluting Stents: Propensity Score-Matched Analysis. Journal of Interventional Cardiology, 2014;27(4):399-407. Journal of Interventional Cardiology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Interventional Cardiology - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1540-8183)
Our news journalists report that additional information may be obtained by contacting J.H. Lee, Yonsei University, Wonju Coll Med, Inst Lifestyle Med, Wonju 220701, Gangwon Do, South Korea. Additional authors for this research include J.W. Lee, Y.J. Youn, M.S. Ahn, S.G. Ahn, J.Y. Kim, B.S. Yoo, S.H. Lee, E. Choi and J. Yoon (see also Drugs and Therapies).
Keywords for this news article include: Gangwon Do, South Korea, Asia, Antineoplastics, Drugs, Drugs and Therapies, Everolimus, Immunosuppressive Agents, MTOR Inhibitors, MTOR Kinase Inhibitors, Stent Thrombosis, Therapy, Tyrosine Kinase Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC